Test-bed 1: Mesenchymal Stromal Cells

Test-bed 1 projects encompass activities across all aspects of a closed-loop manufacturing system for mesenchymal stromal cells (MSCs). MSCs are currently being explored for their anti-inflammatory and pro-regenerative potential to treat a wide range of chronic diseases.  However, issues remain in scaling these therapies, as well as identifying critical quality attributes for clinical potency.  Our current projects address these major roadblocks:

Projects

•    Identification of MSC critical quality attributes through non-destructive, in-process characterization of cellular outputs (Thrusts 1,3)

•    Development of image-based approaches for predicting and assessing the effects of manufacturing environments on MSCs (Thrusts 1,3)

•    On-chip Cell Therapy Potency Platform (Thrusts 2,3)

•    Microcarriers for scale-up and monitoring of MSCs (Thrusts 1,3)

Project Descriptions

Test-Bed 1: On-chip Cell Therapy Potency Platform (Thrust Involved: 2)

• Ted-Bed 1: Development of image-based approaches for predicting and assessing the effects of manufacturing environments on MSCs. (Thrust Involved: 1)
• Test-Bed 1: Microcarriers for scale-up and monitoring of MSCs (Thrusts Involved: 1 & 3)
• Test-Bed 1: Identification of MSC critical quality attributes through non-destructive, in-process characterization of cellular outputs (Thrust Involved: 1)
• Test-Bed 1: Leveraging mitochondrial bioenergetics for long-term quality control and near-term optimization of live MSC potency (Thrust Involved: 3)
• Test-Bed 1: Scalable manufacturing of gene-modified primary natural killer cell therapies (Thrust Involved: All)